Eli Lilly and Company has emerged as in the manufacturing of tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant potential to improve glycemic control and reduce the risk of cardiovascular disease. The sophisticated synthesis of tirzepatide involves a series of metic